Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| TAR DNA-Binding Protein 43 (TDP-43) Overview | 6 | 1 |
| Therapeutics Development | 7 | 3 |
| TAR DNA-Binding Protein 43 (TDP-43) Products under Development by Stage of Development | 7 | 1 |
| TAR DNA-Binding Protein 43 (TDP-43) Products under Development by Therapy Area | 8 | 1 |
| TAR DNA-Binding Protein 43 (TDP-43) Products under Development by Indication | 9 | 1 |
| TAR DNA-Binding Protein 43 (TDP-43) Pipeline Products Glance | 10 | 2 |
| Late Stage Products | 10 | 1 |
| Early Stage Products | 11 | 1 |
| TAR DNA-Binding Protein 43 (TDP-43) Products under Development by Companies | 12 | 2 |
| TAR DNA-Binding Protein 43 (TDP-43) Therapeutics Assessment | 14 | 5 |
| Assessment by Monotherapy/Combination Products | 14 | 1 |
| Assessment by Mechanism of Action | 15 | 1 |
| Assessment by Route of Administration | 16 | 1 |
| Assessment by Molecule Type | 17 | 2 |
| TAR DNA-Binding Protein 43 (TDP-43) Companies Involved in Therapeutics Development | 19 | 5 |
| Biogen, Inc. | 19 | 1 |
| ImStar Therapeutics Inc. | 20 | 1 |
| Primary Peptides, Inc. | 21 | 1 |
| SK Biopharmaceuticals Co., Ltd. | 22 | 1 |
| TauRx Therapeutics Ltd. | 23 | 1 |
| TAR DNA-Binding Protein 43 (TDP-43) Drug Profiles | 24 | 9 |
| IMS-088 Drug Profile | 24 | 1 |
| NI-205 Drug Profile | 25 | 1 |
| Small Molecule to Inhibit TDP-43 for Amyotrophic Lateral Sclerosis Drug Profile | 26 | 1 |
| Small Molecules to Inhibit TANA for ALS, Dementia and Alzheimer's Disease Drug Profile | 27 | 1 |
| Small Molecules to Inhibit TDP-43 for Amyotrophic Lateral Sclerosis Drug Profile | 28 | 1 |
| Synthetic Peptide to Inhibit TDP-43 for Amyotrophic Lateral Sclerosis Drug Profile | 29 | 1 |
| TRx-0237 Drug Profile | 30 | 3 |
| TAR DNA-Binding Protein 43 (TDP-43) Dormant Projects | 33 | 1 |
| TAR DNA-Binding Protein 43 (TDP-43) Featured News &Press Releases | 34 | 11 |
| Nov 23, 2015: Aquinnah Pharmaceuticals Receives $680,000 Grant from NINDS To Advance New Therapies for ALS | 34 | 1 |
| Jan 20, 2015: First Evidence of Potential Efficacy of Tau Aggregation Inhibitor Therapy in Alzheimer s Disease | 34 | 1 |
| Sep 25, 2014: Proteome Sciences signs $2m contract with Genting TauRx Diagnostic Centre to develop diagnostic panels to detect Alzheimer's disease and monitor treatment efficacy | 35 | 1 |
| Sep 22, 2014: TauRx Therapeutics Achieves Enrolment Target for Second Phase III Clinical Trial of LMTX in Alzheimer's Disease | 36 | 1 |
| Jul 15, 2014: TauRx Therapeutics Achieves Enrolment Target in the First of Its Two Phase III Clinical Trials of LMTX in Alzheimer s Disease | 37 | 1 |
| Jun 18, 2014: University Hospitals Case Medical Center now enrolling patients in clinical trial for Frontotemporal Dementia | 38 | 1 |
| Mar 27, 2014: TauRx Chairman to present at scientific symposium focused on advances in Alzheimer's treatments | 39 | 1 |
| Mar 24, 2014: TauRx Therapeutics to present at Social Care Conference in London on 25th | 40 | 1 |
| Jan 09, 2014: First German Patients Enroll in Phase 3 Clinical Trials of LMTX for Alzheimer's Disease | 40 | 1 |
| Jan 06, 2014: TauRx Expands Alzheimer's Clinical Trials in the United States | 41 | 1 |
| Nov 26, 2013: ImStar Therapeutics Selects Lead Drug Candidate for ALS | 41 | 1 |
| Oct 03, 2013: Professor Claude Wischik, Chairman of TauRx, highlights future consequences of Alzheimer s Disease at annual psychogeriatric conference in Korea | 42 | 1 |
| Sep 19, 2013: TauRx achieves milestone in global Phase 3 clinical trials of LMTX for Alzheimer's Disease | 42 | 1 |
| Jun 10, 2013: TauRx Therapeutics And Toronto Memory Program Announce Canadian Launch Of Phase III Clinical Trials Of LMTX For Treatment Of Alzheimer's Disease | 43 | 1 |
| May 22, 2013: TauRx Therapeutics Enrolls First Patient In Phase III Clinical Trials Of LMTX For Treatment Of Alzheimer's Disease In UK | 44 | 1 |
| Appendix | 45 | 2 |
| Methodology | 45 | 1 |
| Coverage | 45 | 1 |
| Secondary Research | 45 | 1 |
| Primary Research | 45 | 1 |
| Expert Panel Validation | 45 | 1 |
| Contact Us | 45 | 1 |
| Disclaimer | 46 | 1 |